PortalPublikationenAllogeneic hematopoietic cell transplantation in patients wi...

Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer: A study of the Chronic Malignancies Working Party of the EBMT

Standard

Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer: A study of the Chronic Malignancies Working Party of the EBMT. / Nabergoj, Mitja; Mauff, Katya; Beelen, Dietrich; Ganser, Arnold; Kröger, Nicolaus; Stölzel, Friedrich; Finke, Jürgen; Passweg, Jakob; Cornelissen, Jan; Schub, Natalie; Veelken, Joan Hendrik; Beguin, Yves; Wilson, Keith; Zuckerman, Tsila; Hunault-Berger, Mathilde; Lioure, Bruno; Porras, Rocio Parody; Turlure, Pascal; Kerre, Tessa; Koster, Linda; Hayden, Patrick J; Onida, Francesco; Scheid, Christof; Chalandon, Yves; Robin, Marie; Yakoub-Agha, Ibrahim.

in: BONE MARROW TRANSPL, Jahrgang 57, Nr. 7, 07.2022, S. 1072-1078.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Nabergoj, M, Mauff, K, Beelen, D, Ganser, A, Kröger, N, Stölzel, F, Finke, J, Passweg, J, Cornelissen, J, Schub, N, Veelken, JH, Beguin, Y, Wilson, K, Zuckerman, T, Hunault-Berger, M, Lioure, B, Porras, RP, Turlure, P, Kerre, T, Koster, L, Hayden, PJ, Onida, F, Scheid, C, Chalandon, Y, Robin, M & Yakoub-Agha, I 2022, 'Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer: A study of the Chronic Malignancies Working Party of the EBMT', BONE MARROW TRANSPL, Jg. 57, Nr. 7, S. 1072-1078. https://doi.org/10.1038/s41409-022-01686-7

APA

Nabergoj, M., Mauff, K., Beelen, D., Ganser, A., Kröger, N., Stölzel, F., Finke, J., Passweg, J., Cornelissen, J., Schub, N., Veelken, J. H., Beguin, Y., Wilson, K., Zuckerman, T., Hunault-Berger, M., Lioure, B., Porras, R. P., Turlure, P., Kerre, T., ... Yakoub-Agha, I. (2022). Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer: A study of the Chronic Malignancies Working Party of the EBMT. BONE MARROW TRANSPL, 57(7), 1072-1078. https://doi.org/10.1038/s41409-022-01686-7

Vancouver

Nabergoj M, Mauff K, Beelen D, Ganser A, Kröger N, Stölzel F et al. Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer: A study of the Chronic Malignancies Working Party of the EBMT. BONE MARROW TRANSPL. 2022 Jul;57(7):1072-1078. https://doi.org/10.1038/s41409-022-01686-7

Bibtex

@article{d7154bf1cad449ccbbff2fb1d372be06,
title = "Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer: A study of the Chronic Malignancies Working Party of the EBMT",
abstract = "We performed a registry study on therapy-related myeloid neoplasm (t-MN), both therapy-related myelodysplastic syndrome (t-MDS) and acute myeloid leukemia (t-AML) following treatment for breast cancer who underwent a first allogeneic hematopoietic cell transplant (allo-HCT). Of 252 identified female patients (median age 57 years), 77% were transplanted for t-AML and 23% for t-MDS, with a median time from breast cancer diagnosis to the diagnosis of tMN and subsequent allo-HCT of 3.7 and 4.6 years, respectively. At transplant, 191 patients were in remission for breast cancer, while 4 were not (57 missing). T-MN was in a complete remission at the time of transplant in 67% of patients. 2-year overall survival, relapse free-survival, relapse incidence and non-relapse mortality were 50%, 45%, 33%, and 22%, respectively. Multivariable analysis revealed that if the t-MN was not in CR pre-transplant, this was associated with lower OS, RFS, and a higher relapse incidence. Seventeen cases of breast cancer recurrence were recorded after a median of 2.4 years post-transplant, and relapse of primary breast cancer accounted for 7% of deaths. This study indicates that allo-HCT for t-MN following treatment for breast cancer shows encouraging transplant outcomes. The incidence of breast cancer relapse post-transplant remains a cause for concern.",
keywords = "Breast Neoplasms/therapy, Female, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation/adverse effects, Humans, Leukemia, Myeloid, Acute/therapy, Middle Aged, Myeloproliferative Disorders, Recurrence, Retrospective Studies, Transplantation Conditioning",
author = "Mitja Nabergoj and Katya Mauff and Dietrich Beelen and Arnold Ganser and Nicolaus Kr{\"o}ger and Friedrich St{\"o}lzel and J{\"u}rgen Finke and Jakob Passweg and Jan Cornelissen and Natalie Schub and Veelken, {Joan Hendrik} and Yves Beguin and Keith Wilson and Tsila Zuckerman and Mathilde Hunault-Berger and Bruno Lioure and Porras, {Rocio Parody} and Pascal Turlure and Tessa Kerre and Linda Koster and Hayden, {Patrick J} and Francesco Onida and Christof Scheid and Yves Chalandon and Marie Robin and Ibrahim Yakoub-Agha",
note = "{\textcopyright} 2022. The Author(s), under exclusive licence to Springer Nature Limited.",
year = "2022",
month = jul,
doi = "10.1038/s41409-022-01686-7",
language = "English",
volume = "57",
pages = "1072--1078",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "7",

}

RIS

TY - JOUR

T1 - Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer: A study of the Chronic Malignancies Working Party of the EBMT

AU - Nabergoj, Mitja

AU - Mauff, Katya

AU - Beelen, Dietrich

AU - Ganser, Arnold

AU - Kröger, Nicolaus

AU - Stölzel, Friedrich

AU - Finke, Jürgen

AU - Passweg, Jakob

AU - Cornelissen, Jan

AU - Schub, Natalie

AU - Veelken, Joan Hendrik

AU - Beguin, Yves

AU - Wilson, Keith

AU - Zuckerman, Tsila

AU - Hunault-Berger, Mathilde

AU - Lioure, Bruno

AU - Porras, Rocio Parody

AU - Turlure, Pascal

AU - Kerre, Tessa

AU - Koster, Linda

AU - Hayden, Patrick J

AU - Onida, Francesco

AU - Scheid, Christof

AU - Chalandon, Yves

AU - Robin, Marie

AU - Yakoub-Agha, Ibrahim

N1 - © 2022. The Author(s), under exclusive licence to Springer Nature Limited.

PY - 2022/7

Y1 - 2022/7

N2 - We performed a registry study on therapy-related myeloid neoplasm (t-MN), both therapy-related myelodysplastic syndrome (t-MDS) and acute myeloid leukemia (t-AML) following treatment for breast cancer who underwent a first allogeneic hematopoietic cell transplant (allo-HCT). Of 252 identified female patients (median age 57 years), 77% were transplanted for t-AML and 23% for t-MDS, with a median time from breast cancer diagnosis to the diagnosis of tMN and subsequent allo-HCT of 3.7 and 4.6 years, respectively. At transplant, 191 patients were in remission for breast cancer, while 4 were not (57 missing). T-MN was in a complete remission at the time of transplant in 67% of patients. 2-year overall survival, relapse free-survival, relapse incidence and non-relapse mortality were 50%, 45%, 33%, and 22%, respectively. Multivariable analysis revealed that if the t-MN was not in CR pre-transplant, this was associated with lower OS, RFS, and a higher relapse incidence. Seventeen cases of breast cancer recurrence were recorded after a median of 2.4 years post-transplant, and relapse of primary breast cancer accounted for 7% of deaths. This study indicates that allo-HCT for t-MN following treatment for breast cancer shows encouraging transplant outcomes. The incidence of breast cancer relapse post-transplant remains a cause for concern.

AB - We performed a registry study on therapy-related myeloid neoplasm (t-MN), both therapy-related myelodysplastic syndrome (t-MDS) and acute myeloid leukemia (t-AML) following treatment for breast cancer who underwent a first allogeneic hematopoietic cell transplant (allo-HCT). Of 252 identified female patients (median age 57 years), 77% were transplanted for t-AML and 23% for t-MDS, with a median time from breast cancer diagnosis to the diagnosis of tMN and subsequent allo-HCT of 3.7 and 4.6 years, respectively. At transplant, 191 patients were in remission for breast cancer, while 4 were not (57 missing). T-MN was in a complete remission at the time of transplant in 67% of patients. 2-year overall survival, relapse free-survival, relapse incidence and non-relapse mortality were 50%, 45%, 33%, and 22%, respectively. Multivariable analysis revealed that if the t-MN was not in CR pre-transplant, this was associated with lower OS, RFS, and a higher relapse incidence. Seventeen cases of breast cancer recurrence were recorded after a median of 2.4 years post-transplant, and relapse of primary breast cancer accounted for 7% of deaths. This study indicates that allo-HCT for t-MN following treatment for breast cancer shows encouraging transplant outcomes. The incidence of breast cancer relapse post-transplant remains a cause for concern.

KW - Breast Neoplasms/therapy

KW - Female

KW - Graft vs Host Disease

KW - Hematopoietic Stem Cell Transplantation/adverse effects

KW - Humans

KW - Leukemia, Myeloid, Acute/therapy

KW - Middle Aged

KW - Myeloproliferative Disorders

KW - Recurrence

KW - Retrospective Studies

KW - Transplantation Conditioning

U2 - 10.1038/s41409-022-01686-7

DO - 10.1038/s41409-022-01686-7

M3 - SCORING: Journal article

C2 - 35459878

VL - 57

SP - 1072

EP - 1078

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 7

ER -